British consumer healthcare group Haleon on Tuesday said it gained full control of its Chinese joint venture after acquiring ...

Haleon PLC closed 10.34% below its 52-week high of £4.18, which the company achieved on March 4th.

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

Haleon entered into an agreement to fully acquire Chinese joint venture Tianjin TSKF Pharmaceuticals in a deal valued at 200 million pounds ($263.8 million), lifting its stake to 100% from 88% ...

Berenberg raised the firm’s price target on Haleon (HLN) to 460 GBp from 457 GBp and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for real-time ...

In a report released today, Iain Simpson from Barclays maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of ...

Haleon has gained full control of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake.

Haleon PLC closed 11.52% short of its 52-week high of £4.18, which the company reached on March 4th.

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...